Trials / Completed
CompletedNCT00958724
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
A Phase 1 Study Of Neratinib (HKI-272) In Combination With Vinorelbine In Japanese Subjects With Advanced Or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs, as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors in Japanese patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neratinib | |
| DRUG | Vinorelbine |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2009-08-13
- Last updated
- 2018-06-28
- Results posted
- 2018-02-26
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00958724. Inclusion in this directory is not an endorsement.